An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions

Chung‐Feng Huang, Ming‐Lung Yu, Pin‐Nan Cheng et al.|The Journal of Infectious Diseases|2019

Cited by 19